Publications

06 Jul 2009
Research & Ideas

Conducting Layoffs: ’Necessary Evils’ at Work

key components for taking care of yourself after performing a necessary evil.” It is important to note, however, that we did not gather data about outcomes in this study, so we cannot conclude that any particular method of handling the... View Details

Keywords: by Martha Lagace

04 Jul 2016
Research & Ideas

Is Your Org Chart Stuck in a Rut? Try a Scientific Experiment

it could drive a reorganization of our existing organizational structures.” Other participants in the refinement stage include a health care professional, who proposed an experiment around the idea of... View Details

Keywords: by Carmen Nobel

November 2016
Case

Pete & Gerry's

By: Jose Alvarez and Natalie Kindred

June 2020
Article

Waiting to Inhale: Reducing Stigma in the Medical Cannabis Industry

By: Kisha Lashley and Timothy G. Pollock

When a new industry category is predicated on a product or activity subject to ‘‘core’’ stigma—meaning its very nature is stigmatized—the actors trying to establish it may struggle to gain the resources they need to survive and grow. To explain the process of reducing... View Details

Keywords: Stigma; Cannabis Industry; Deviance; Public Opinion; Moral Sensibility; Health Care and Treatment

Register to Read

June 2011
Teaching Note

Novasys Medical (TN)

By: Richard G. Hamermesh

Teaching Note for 810027. View Details

Keywords: Product Development; Health Care and Treatment; Policy; Medical Devices and Supplies Industry

23 Dec 2014
First Look

First Look: December 23

with pediatric hospitals in Temple, San Antonio, and Mexico City, and how to structure these partnerships was under active discussion. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/714507-PDF-ENG Harvard Business School Case 514-122 Note on Mobile View Details

Keywords: Carmen Nobel

17 Jan 2012
First Look

First Look: January 17

presents one home healthcare organization's efforts to use telemonitoring to improve the quality of care provided to at-risk patients who were discharged from hospitals and needed home care. After two years... View Details

Keywords: Sean Silverthorne

October 2024
Article

Medicare Part D Protected-Class Policy Is Associated with Lower Drug Rebates

By: Pragya Kakani, Michael Anne Kyle, Amitabh Chandra and Luca Maini

Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher spending. We estimated the association between protected-class status, US-level estimated... View Details

Keywords: Insurance; Health Care and Treatment; Governing Rules, Regulations, and Reforms; United States

March 2024
Article

Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act

By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti

The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details

Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry

June 9, 2023
Article

A Radical Treatment for Insulin Pricing

By: Leemore S. Dafny

In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details

Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States

Register to Read

October 2009 (Revised July 2013)
Case

Gilead Sciences, Inc.: Access Program

By: V. Kasturi Rangan and Katharine Lee

Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients... View Details

Keywords: Health Care and Treatment; Emerging Markets; Product; Sales; Competitive Strategy; Biotechnology Industry; Pharmaceutical Industry

September 2004
Teaching Note

Duke Heart Failure Program, The (TN)

By: Richard M.J. Bohmer

Teaching Note to (9-604-033). View Details

Keywords: Health Care and Treatment; Programs; Civil Society or Community; Service Operations; Relationships

26 Jul 2016
First Look

July 26, 2016

Thomas W. Feeley, Diana J. Mason, Richard L. Schilsky, Ellen L. Stovall, and Shelley Fuld Nasso Abstract—"What Health System Transformations Do You Believe Are Necessary for the Future of Health... View Details

Keywords: Sean Silverthorne

11 Jun 2014
Research & Ideas

In the Future of Sports Investing, Media Is the Best Bet

redefined," Higgins says. "The younger generation doesn't care as much about cable TV." And for older sports fans, mobile devices are gaining popularity because they allow for multitasking. "Wyc Grousbeck was on a tour... View Details

Keywords: by Carmen Nobel; Sports; Financial Services

January 2021 (Revised June 2021)
Case

Hester Pharmaceuticals (A): A Pricing Dilemma

By: Dante Roscini and John Masko

In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details

Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy

January 2006 (Revised May 2007)
Case

Endo Pharmaceuticals (A): From LBO to...?

By: Richard G. Hamermesh and Brian DeLacey

Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details

Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States